Tocilizumab has improved neurological symptoms in a patient with ICI-related steroid-refractory transverse myelitis with high levels of IL-6 in the CSF [138] and demonstrated efficacy in patients with ICI-mediated cerebritis [139]. Here, IL6 is linked to transverse myelitis.